317 related articles for article (PubMed ID: 15577675)
41. [Effectiveness of tissue microarray technique for the assessment of estrogen and progesterone receptors expression in endometrioid endometrial cancer--preliminary report].
Gottwald L; Sek P; Kubiak R; Pasz-Walczak G; Piekarski J; Szwalski J; Suzin J; Tyliński W; Hendzel K; Jeziorski A
Ginekol Pol; 2012 May; 83(5):342-6. PubMed ID: 22708330
[TBL] [Abstract][Full Text] [Related]
42. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
43. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.
Zannoni GF; Vellone VG; Arena V; Prisco MG; Scambia G; Carbone A; Gallo D
Virchows Arch; 2010 Jul; 457(1):27-34. PubMed ID: 20552366
[TBL] [Abstract][Full Text] [Related]
44. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
45. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
46. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status.
Kappes H; Goemann C; Bamberger AM; Löning T; Milde-Langosch K
Pathobiology; 2001; 69(3):136-42. PubMed ID: 11872959
[TBL] [Abstract][Full Text] [Related]
47. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
48. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
49. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
[TBL] [Abstract][Full Text] [Related]
50. Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma.
Yoo SH; Park BH; Choi J; Yoo J; Lee SW; Kim YM; Kim KR
Mod Pathol; 2012 Nov; 25(11):1496-507. PubMed ID: 22766790
[TBL] [Abstract][Full Text] [Related]
51. Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Fadare O; Parkash V; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Rawish KR; Hecht JL; Desouki MM
Hum Pathol; 2013 Dec; 44(12):2814-21. PubMed ID: 24119561
[TBL] [Abstract][Full Text] [Related]
52. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
[TBL] [Abstract][Full Text] [Related]
53. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
54. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
[TBL] [Abstract][Full Text] [Related]
56. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
[TBL] [Abstract][Full Text] [Related]
57. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
Sherman ME; Bur ME; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703
[TBL] [Abstract][Full Text] [Related]
58. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
60. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
Haley SL; Malhotra RK; Qiu S; Eltorky ME
Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]